Wednesday, July 11, 2012

Biopharma Stocks Reporting on Lung Cancer Developments: SBFM,OGXI

Biopharma Stocks Reporting on Lung Cancer Developments: SBFM,OGXINorthern, WI 7/11/12 (StreetBeat) --, an investor research portal specializing in sector research including biotech and pharma stocks, issues a snapshot of recent news from biopharma stocks reporting developments for the treatment of lung cancer. Sunshine Biopharma Inc. (OTCBB: SBFM) reported news on its lead compound, Adva-27a and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced an update on its lead product, custirsen.

According to OncoGenex's press release, "Lung cancer is the second most common cancer in both men and women and the leading cause of cancer-related death. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. This year, in the United States alone, approximately 226,160 new cases of lung cancer will be diagnosed and an estimated 160,340 patients will die of the disease. "

Sunshine Biopharma Inc. (OTCBB: SBFM) recently reported that it completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer.

Since reporting its news Sunshine Biopharma stock has more than doubled in recent trading and is currently trading at $0.54.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) reported news yesterday on the clinical development program for custirsen and its plans to initiate a Phase 3 clinical trial in non-small cell lung cancer (NSCLC).The trial, planned to begin enrollment later this year, will evaluate the potential survival benefit of combining custirsen with docetaxel, a standard second-line chemotherapy treatment used in patients who have progressed after initial, or first-line, treatment has failed.

The Phase 3 trial will be an international, randomized, open-label study that will enroll approximately 1,100 patients with advanced or metastatic NSCLC who have been previously treated with a first-line platinum-based chemotherapy. Patients will be randomized to receive custirsen plus docetaxel or docetaxel alone. The primary objective of the study will be overall survival with additional secondary and exploratory analyses of other efficacy outcomes and biomarker relationships. Two formal interim analyses are planned for stopping the trial early based on inadequate evidence of clinical benefit or futility. No interim analyses for claiming efficacy are planned.

Custirsen, its lead product, is designed to block production of clusterin, a cell survival protein that is commonly overexpressed in several cancer types and in response to anticancer treatments.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is trading at $14.46, up 0.20 (1.40%) at the time of this report, with a morning high of $14.58.

About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.

About OncoGenex Pharmaceuticals (NASDAQ: OGXI)
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

About is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas:
Follow on Twitter!/Investorideas
Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

800-665-0411 - Source –

Please contact for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

No comments:

Post a Comment